TY - JOUR
T1 - Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
AU - Caffo, Orazio
AU - Gasparro, Donatello
AU - Di Lorenzo, Giuseppe
AU - Volta, Alberto Dalla
AU - Guglielmini, Pamela
AU - Zucali, Paolo
AU - Bortolus, Roberto
AU - Cavo, Alessia
AU - Ceresoli, Giovanni
AU - Chiari, Rita
AU - Fornarini, Giuseppe
AU - Fratino, Lucia
AU - Iaculli, Alessandro
AU - Maruzzo, Marco
AU - Masini, Cristina
AU - Morelli, Franco
AU - Mucciarini, Claudia
AU - Procopio, Giuseppe
AU - Sabbatini, Roberto
AU - Verri, Elena
AU - Kinspergher, Stefania
AU - Maines, Francesca
AU - Messina, Carlo
AU - Veccia, Antonello
AU - Donini, Maddalena
PY - 2020/11
Y1 - 2020/11
N2 - Background: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC). Patients and methods: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality. Results: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13–41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). Conclusions: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC.
AB - Background: Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the risk of mortality is influenced by cancer type or ongoing anti-cancer treatments. An interesting debate concerning the potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in the case of prostate cancer (PC), and the aim of this multi-centre cohort study was to investigate the incidence and outcomes of SARS-CoV-2 infection in patients with metastatic castration-resistant prostrate cancer (mCRPC). Patients and methods: We retrospectively reviewed the clinical records of patients with mCRPC who developed SARS-CoV-2 infection, and recorded their baseline clinical characteristics, their history of PC and SARS-CoV-2 infection, and their oncological status and treatment at the time of infection. The primary study end point was the death rate and the possible impact of the patients' PC-related history and treatments on mortality. Results: Thirty-four of the 1433 patients with mCRPC attending the participating centres (2.3%) developed SARS-CoV-2 infection, 22 (64.7%) of whom were hospitalised. Most of the patients were symptomatic, the most frequent symptoms being fever (70.6%), dyspnoea (61.8%), cough (52.9%) and fatigue (38.2%). After a median follow-up of 21 days (interquartile range: 13–41), 13 patients had died (38.2%), 17 recovered (50.0%) and four (11.7%) were still infected. The number of treatments previously administered for mCRPC had a significant impact on mortality (p = 0.004). Conclusions: Our findings contribute additional data to the current debate concerning the postulated protective role of ADT, which seems to be less in patients with metastatic PC.
KW - Androgen deprivation therapy
KW - COVID-19
KW - Metastatic castration-resistant prostate cancer
KW - SARS-CoV-2 infection
UR - http://www.scopus.com/inward/record.url?scp=85092919368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092919368&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2020.09.018
DO - 10.1016/j.ejca.2020.09.018
M3 - Article
AN - SCOPUS:85092919368
VL - 140
SP - 140
EP - 146
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
ER -